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Abstract Cutaneous T-cell lymphomas (CTCL) are charac-
terized by the presence of chronically inflamed skin lesions
containing malignant T cells. Early disease presents as limited
skin patches or plaques and exhibits an indolent behavior. For
many patients, the disease never progresses beyond this stage,
but in approximately one third of patients, the disease be-
comes progressive, and the skin lesions start to expand and
evolve. Eventually, overt tumors develop and the malignant T
cells may disseminate to the blood, lymph nodes, bone mar-
row, and visceral organs, often with a fatal outcome. The tran-
sition from early indolent to progressive and advanced disease
is accompanied by a significant shift in the nature of the
tumor-associated inflammation. This shift does not appear to
be an epiphenomenon but rather a critical step in disease pro-
gression. Emerging evidence supports that the malignant T
cells take control of the inflammatory environment, suppress-
ing cellular immunity and anti-tumor responses while promot-
ing a chronic inflammatory milieu that fuels their own expan-
sion. Here, we review the inflammatory changes associated
with disease progression in CTCL and point to their wider
relevance in other cancer contexts. We further define the term
Bmalignant inflammation^ as a pro-tumorigenic inflammatory
environment orchestrated by the tumor cells and discuss some
of the mechanisms driving the development of malignant in-
flammation in CTCL.
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Introduction
Cutaneous T-cell lymphomas (CTCL) are characterized by the
presence of malignant T cells in chronically inflamed skin
lesions. Mycosis fungoides (MF) is the predominant clinical
variant comprising 54–72 % of all cases [1–3]. Classically,
MF presents as erythematous skin patches bearing strong re-
semblance to benign inflammatory dermatoses. Early disease,
which is characterized by limited patches or plaques (Fig. 1a),
typically exhibits an indolent behavior and a very favorable
prognosis with normal life expectancy [1–3]. For many pa-
tients, the disease never progresses beyond this stage, but for
about one third of patients the skin lesions start to spread
(Fig. 1b, c) and, eventually, overt tumors and generalized
erythroderma may develop [2]. In advanced disease, the ma-
lignant T cells can further disseminate to the lymphatic sys-
tem, blood, bone marrow, and internal organs. There is a
stage-dependent decrease in survival, and patients with late
stages of CTCL have a median life expectancy of less than
4 years [1–5]. The risk of disease progression rises
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significantly as the disease advances highlighting that it be-
comes increasingly aggressive [4]. Sézary syndrome (SS) is a
particular aggressive variant of CTCL that can arise de novo
or, rarely, ensue after years of chronic MF [1, 4–6]. The char-
acteristics of SS include generalized erythroderma, lymphade-
nopathy, and peripheral blood involvement, classifying SS as
an advanced clinical stage of CTCL [1, 2, 6]. BecauseMF and
SS are the best studied forms of CTCL and collectively com-
prise the majority of cases, the term CTCL will in the follow-
ing generally refer to these two clinical variants [1, 2].
The malignant T cells typically display the phenotype of
CD4+ memory T lymphocytes and express skin-homing
receptors such as cutaneous lymphocyte antigen (CLA),
CC chemokine receptor 4 (CCR4), and CCR10 [1, 7–11].
In low-grade MF, the malignant T cells also express CXC
chemokine receptor 3 (CXCR3), which promotes their re-
cruitment to the dermis and epidermis where the corre-
sponding ligands (CXCL9, CXCL10, and CXCL11) are
synthesized [8, 12–14]. Based on the expression of
CCR7, L-selectin, and CD27, it has further been reported
that the phenotype of the malignant T cells resembles that
of skin resident effector memory T cells in MF and that of
central memory T cells in SS [9]. However, many charac-
teristics of the malignant T cells change during disease
progression, and there seems to be a relatively high degree
of heterogeneity and plasticity within the malignant popu-
lation [15].
The etiology of MF and SS remains an enigma.
Demographic patterns in the incidence of CTCL have
been reported, but no environmental triggers have yet
been identified [16, 17]. Likewise, no convincing evi-
dence showing an etiologic role of infectious agents in
CTCL has been provided, albeit infections may aggravate
the disease [18]. A recent series of studies profiled the
genomic landscape of CTCL [19–25]. Collectively, the
results demonstrated that the genomic landscape is very
heterogeneous, and that the disease is not driven by a few
well-defined somatic mutations, copy number variations,
or fusion proteins. Somatic genetic alterations were, how-
ever, frequently found in genes involved in specific cel-
lular processes and signaling pathways, including epige-
netic regulation, DNA damage response, cell cycle con-
trol, programmed cell death, T cell receptor (TCR) signal-
ing, as well as the nuclear factor-kappa B (NF-κB) and
Janus kinase (Jak)/signal transducer and activator of tran-
scription (Stat) pathways [19–25]. Accordingly, numerous
studies have previously raised these cellular processes and
pathways as key players in the pathogenesis of CTCL.
Three studies found a high prevalence of ultraviolet
(UV) light signature mutations in patients with MF and
leukemic CTCL [19, 22, 25]. No correlation between the
presence of the UV light signature and previous therapeu-
tic UV light exposure was observed in leukemic patients,
arguing that accumulated lifetime exposure to natural UV
light induced the UV mutational signature, thereby chal-
lenging the view that the disease originates from central
memory T cells rather than skin resident memory T cells
[19, 22].
Despite stage-appropriate treatment, a significant sub-
set of CTCL patients, eventually, develop progressive dis-
ease [2, 26]. Given the profoundly reduced survival and
increased clinical aggressiveness of advanced CTCL, it is
of outmost importance to map the mechanisms that under-
lie disease progression [4, 5]. A better understanding of
these mechanisms may lead to the development of more
efficient strategies to diagnose, prevent and treat progres-
sive disease. CTCL lesions can display varying degrees of
inflammation (Fig. 2), and a large number of studies have
highlighted changes in the tumor-associated inflammatory
environment as a critical checkpoint in the transition from
early indolent to progressive and advanced disease. Here,
we review the inflammatory changes associated with dis-
ease progression in CTCL and outline some of the mech-
anisms that appear to drive the development of malignant
inflammation—a pro-tumorigenic inflammatory environ-
ment orchestrated by the tumor cells.
Fig. 1 Progressive MF. a–c Example of a patient with progressive MF
that during a 3-year period (2002–2004) presents with increasing skin
involvement and inflammation. The patient progressed from a clinical
stage IA disease with limited patches and plaques to b, c clinical stage
IB disease with patches and plaques involvingmore than 10% of the skin
surface area
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The inflammatory environment becomes Th2-biased
during the clinical course of CTCL
In early disease stages, the skin lesions contain of a small
population of malignant T cells immersed within a dense in-
filtrate of reactive immune cells. A significant proportion of
the immune cells are activated CD8+ T cells and T helper 1
(Th1) cells expressing cytotoxic molecules, implying that ear-
ly inflammation encompasses a cell-mediated anti-tumor re-
sponse that actively suppresses the expansion of the malignant
cells [27–33]. Indeed, reactive CD4+ Tcells, CD8+ Tcells and
natural killer (NK) cells isolated from CTCL patients are able
to kill autologous malignant T cells in vitro, and high numbers
of CD8+ lymphocytes in skin lesions and/or blood are linked
to a favorable prognosis [30, 32, 34–37].
Disease progression is, however, associated with increas-
ing expression of Th2 markers (e.g., GATA-3) and cytokines
(e.g. interleukin (IL)-4, IL-5, and IL-13) concomitant with
declining expression of Th1 factors such as T cell-specific T-
box transcription factor (T-bet), interferon gamma (IFN-γ),
Stat4, and IL-12 [33, 38–43]. Accordingly, late-stage CTCL
is characterized by a Th2-dominated tumor microenvironment
and a paucity of benign Th1 cells and CD8+ T cells [32–34,
37–39, 41]. The growing Th2-bias is believed to be a key
process suppressing cellular immunity and anti-tumor re-
sponses in CTCL, and the impairment of the immune defense
can especially be seen in patients with advanced disease who
often suffer from severe and sometimes fatal bacterial infec-
tions [27, 44].
Changes in the chemokine profile facilitate
the development of a Th2-biased tumor
microenvironment and direct the trafficking
of the malignant T cells
Parallel to the shift in the balance of Th1 and Th2 cytokines,
there is a decrease in chemokines that preferentially attract
Th1-associated inflammatory cells, such as CXCL9 and
CXCL10, and an increase in chemokines that primarily attract
Th2-associated inflammatory cells [14]. For example,
Miyagaki et al. demonstrated that fibroblasts in early CTCL
lesions express high levels of the chemokines CXCL9 and
CXCL10, which preferentially attract Th1 cells, CD8+ Tcells,
and NK cells [45, 46]. Secretion of these chemokines was
triggered in explanted CTCL skin fibroblasts upon co-
stimulation with IFN-γ and LIGHT (TNFSF14). Whereas
the expression of LIGHT was increased in advanced when
compared with early disease, the expression of its receptor,
herpesvirus entry mediator (HVEM), was decreased. The au-
thors found a direct correlation between the expression levels
of CXCL9, CXCL10, and HVEM, indicating that downregu-
lation of HVEM and IFN-γ, at least partly, is responsible for
the decreased expression of CXCL9 and CXCL10 during dis-
ease progression [45]. Conversely, the concentrations of Th2-
associated chemokines such as CCL17, CCL18, CCL22, and
CCL26 have been shown to increase from early to advanced
disease [47–50]. These chemokines are primarily secreted by
diverse non-malignant cell types within the skin lesions, and
by favoring recruitment of Th2 cells relative to that of Th1
cells, most likely play a central role in CTCL progression
through promoting a Th2-dominated inflammatory microen-
vironment [7, 46, 47, 50–53].
In early disease, the malignant T cells express CXCR3,
the receptor for CXCL9 and CXCL10, and the CXCR3-
CXCL9/CXCL10 axis has been proposed to be important
for the dermal and epidermal accumulation of the malig-
nant T cells at this stage. However, similar to CXCL9 and
CXCL10, the expression of CXCR3 also decreases during
disease progression, which is accompanied by a gradual loss
of epidermotropism [12, 13, 45]. In contrast, CCR4, the re-
ceptor for CCL17 and CCL22, is continuously expressed by
the malignant T cells and, in line with the upregulation of
CCL17 and CCL22, the number of CCR4-positive T cells
increases in later disease stages [10, 47, 49]. A recent phase
I/II clinical study of the humanized anti-CCR4 antibody,
mogamulizumab, showed promising results in heavily
pretreated patients, supporting an important role of the
CCR4-CCL17/CCL22 axis in the pathogenesis of CTCL
[54]. In advanced disease stages, the expression of the chemo-
kine receptor CCR6 and its ligand CCL20 is increased in the
lesional skin [55, 56]. Of interest, Ikeda and co-workers
Fig. 2 MF lesions display
different levels of inflammation.
a–c Illustrative skin lesions from
a patient with MF displaying
varying degrees of inflammation
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reported that disruption of CCL20-CCR6 interactions
inhibited disease spread in NOG mice inoculated with
CCR6+CCL20+ malignant CTCL cells, arguing that upregu-
lation of the CCR6-CCL20 axis might promote malignant
dissemination in some cases [57]. Collectively, these findings
emphasize that the expression of chemokines and chemokine
receptors is dynamic during the progression of CTCL, and that
distinct chemokine-chemokine receptor interactions shape the
inflammatory microenvironment and the trafficking of malig-
nant T cells at different disease stages.
The expression of pro-tumorigenic cytokines
increases during disease progression
Besides the rise in Th2-associated cytokines and chemokines,
the expression of a range of cytokines, including IL-10, IL-15,
IL-16, IL-17A, IL-17F, IL-22, and IL-32 also increases during
the clinical course of the disease [55, 58–65]. As briefly de-
scribed below, all of these cytokines have been reported to
play pathogenic roles in CTCL. For instance, IL-10 was
shown to suppress Th1 cytokine production by CTCL cells,
and malignant CTCL cells impede dendritic cell maturation,
as well as activation of benign T cells, in an IL-10-dependent
manner, indicating that IL-10 contributes to the suppression of
cellular immunity and anti-tumor responses [66–68]. IL-16 is
a growth factor and a chemo-attractant for CD4+ T cells.
Accordingly, evidence supports that elevated levels of IL-16
contribute to the cutaneous accumulation of the malignant T
cells by augmenting their intradermal proliferation and poten-
tiating their recruitment into the skin [49, 69]. The expression
of IL-17A and IL-17F is heterogeneous and confined to a
subset of patients which is likely the cause of discrepant re-
ports regarding their expression in CTCL [55, 62, 70–73].
High expression of IL-17F has been associated with signifi-
cantly increased risk of disease progression independently of
disease stage, sex, and age at the time of diagnosis and IL-17A
with neutrophil infiltration in CTCL lesions [62, 70]. In agree-
ment, marked infiltration of neutrophils is only observed in a
subset of CTCL patients and their accumulation has been as-
sociated with an aggressive disease course [70, 74]. IL-22 has
been reported to correlate with the expression of CCL20 in
CTCL lesions, and siRNA-mediated knockdown of IL-22 re-
ceptor alpha (IL-22RA) in malignant CTCL cells inhibited the
expression of CCL20, providing a possible link between IL-
22, the CCR6-CLL20 axis, and malignant dissemination [55,
56]. Finally, IL-32 has been shown to promote the prolifera-
tion and survival of malignant CTCL cells via NF-κB- and
mitogen-activated protein kinase (MAPK)-dependent mecha-
nisms [64, 65].
Taken together, a plethora of distinct cytokines and
chemokines are upregulated during the progression of CTCL
and seem to facilitate expansion of the malignant T cells.
Disease progression, thus, appears to be associated with a shift
in the nature and cellular composition of the tumor-associated
inflammatory environment from partly anti-tumorigenic to
pro-tumorigenic. This raises the key question—what is driv-
ing these inflammatory changes? Are the changes an epiphe-
nomenon of a frustrated Bhost^ anti-tumor immune response,
or are they an important ingredient of a cancer-cell-driven
escape from the Bhost^ immunity and a result of a Bparasitic^
exploitation of the microenvironment orchestrated by the ma-
lignant T cells?
The malignant T cells promote the development
of a lesional Th2-bias
Providing a pivotal clue to this question, several reports have
shown that the malignant T cells in advanced stages express
high levels of the Th2-cytokines IL-4, IL-5, and IL-13 and low
levels of IFN-γ [41, 75, 76]. At the molecular level, the
skewed Th2 cytokine profile, at least partly, seems to be me-
diated by a progressive dysregulation of the Jak/Stat pathway
and increased expression of the Th2-lineage-specific tran-
scription factor GATA-3 [33, 43]. Under normal conditions,
Stat proteins are only transiently activated but genetic alter-
ations, epigenetic changes, persistent cytokine signaling, and
infections appear to drive constitutive activation of Stat3,
Stat5, and Stat6 signaling in the malignant T cells during the
clinical course of CTCL [19, 21, 24, 41, 43, 77–83]. Aberrant
activation of these transcription factors not only fosters the
growth and survival of the malignant T cells but also stimu-
lates the secretion of Th2 cytokines [43, 75, 80]. Expression of
Stat4, which promotes Th1 differentiation and IFN-γ expres-
sion, is on the contrary very frequently lost in advanced dis-
ease [42, 43, 84–86]. Evidence suggests that aberrant activa-
tion of Stat5 in the malignant T cells induces expression of
miR-155 which subsequently inhibits the expression of Stat4
[84, 87, 88]. The mechanisms underlying the increased ex-
pression of GATA-3 in the malignant Tcells have not yet been
elucidated. However, it is noteworthy that several large-scale
genomic studies recently found that the ZEB1 gene, which is a
potent transcriptional repressor of GATA-3, is somatically
targeted by deleterious mutations or deleted in 45–65 % of
patients with advanced CTCL [19, 21, 22, 25].
It is well established that Th1 cytokines enforce Th1- and
repress Th2-mediated inflammation and vice versa, suggest-
ing that the phenotypic shift of the malignant T cells towards a
Th2 profile might instigate the development of the generalized
Th2-bias in CTCL lesions. Indeed, a recent study by Guenova
et al. demonstrated that benign T cells isolated from patients
with leukemic CTCL displayed reduced Th2 and enhanced
Th1 responses when cultured separately from the malignant
T cells [76]. Likewise, T cells from healthy donors demon-
strated significantly reduced ability to secrete IFN-γwhen co-
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cultured with leukemic CTCL cells. The malignant T cell-
induced suppression of IFN-γ production by the healthy T
cells was completely blocked by neutralizing antibodies
against IL-4 and IL-13. Notably, separate culture had no effect
on the production of Th1 and Th2 cytokines by isolated ma-
lignant T cells. The authors further addressed how treatment
with a variety of modalities, including UVB phototherapy,
extracorporal photopheresis, low-dose alemtuzumab, and sys-
temic chemotherapy with gemcitabine influenced the frequen-
cy of benign T cells expressing IFN-γ and IL-4 in leukemic
CTCL patients [76]. In line with the in vitro results, they found
that in-spite of distinct mechanisms of action, all treatment
modalities that successfully reduced the malignant T cell bur-
den strongly increased the frequency of IFN-γ-expressing,
and decreased the frequency of IL-4-expressing, benign T
lymphocytes [76]. Collectively, these findings imply that pro-
gressive dysregulation of the Jak/Stat pathway and upregula-
tion of GATA-3 in the malignant T cells lead to their increased
synthesis of IL-4 and IL-13 which suppresses benign Th1
responses and promotes a generalized Th2-bias.
Malignant T cells may also contribute indirectly to the
shifting Th1/Th2 balance by regulating the expression of
chemokines within the lesional skin. Whereas IFN-γ prefer-
entially induces expression of CXCL9 and CXCL10, IL-4 and
IL-13 primarily induce expression of CCL17, CCL18,
CCL22, and CCL26 [46, 89–94]. It is therefore plausible that
the increased expression of Th2 cytokines and decreased ex-
pression of Th1 cytokines by the malignant T cells create a
positive feedback loop by promoting the secretion of Th2
chemokines from benign cells in the tumor microenvironment
(e.g., tumor-associated macrophages, fibroblasts, and
keratinocytes). This, in turn, favors the recruitment of Th2
cells, ultimately, leading to enhanced expression of Th2 and
decreased expression of Th1 cytokines. Accordingly, signifi-
cant correlations between the expression of IL-4 and CCL18,
as well as IL-4 and CCL26, in CTCL skin lesions were pre-
viously reported [48, 50].
The malignant Tcells suppress anti-tumor immunity
via cell contact-dependent and cell
contact-independent mechanisms
The malignant T cells may, however, not only suppress anti-
tumor immunity bymodulating the nature of the inflammatory
microenvironment but can also directly kill or suppress the
activation and proliferation of benign immune cells. For ex-
ample, aberrant activation of Stat5 has been shown to induce
expression of the B7 family member, CD80 (B7-1), on the
surface of malignant CTCL cells [95]. CD80 is an immuno-
regulatory molecule that can deliver growth-inhibitory signals
to activated T cells via the receptor CD152 (CTLA-4) [96].
Whereas depletion of CD80 in the malignant T cells did not
influence their proliferation or viability, the malignant T cells
inhibited the proliferation of benign T cells in a CD152- and
CD80-dependent manner [95]. The Jak/Stat pathway was,
likewise, proposed to induce malignant T cell expression of
another inhibitory B7 family member, namely PD-L1 (B7-
H1), which has been implicated in benign T cell suppression
and tumor immune evasion in CTCL [97–100]. Interestingly,
it was demonstrated that the malignant T cells can be targeted
by PD-L1-specific cytotoxic T cells, indicating that the im-
mune system is able to react to immune escape mechanisms
of the tumor cells [101]. The malignant T cells also frequently
express high levels of Fas ligand (FasL) which can induce
apoptosis by engaging the death receptor, Fas, on target cells
[102]. Malignant CTCL cells have been shown to induce
FasL-mediated T cell apoptosis in vitro, and the numbers of
CD8+ T cells are inversely distributed with FasL-positive tu-
mor cells in situ, supporting that the malignant T cells utilize
FasL to kill tumor-reactive T cells [102, 103]. Due to loss of
Fas expression, somatic inactivating mutations and deletions
of the FAS and ARID1a genes or increased expression of anti-
apoptotic proteins such as c-FLIP, the malignant T cells typi-
cally develop resistance to FasL-mediated apoptosis which
contrarily protects them from activation-induced apoptosis
and T cell-mediated cytotoxicity [19, 21, 22, 104–107].
In addition to these cell contact-dependent mechanisms,
the malignant T cells may also directly suppress the im-
mune system via secretion of soluble factors. Aberrant ac-
tivation of the Jak/Stat pathway has, for example, been
shown to induce expression of the immunoregulatory cy-
tokines IL-10 and transforming growth factor beta
(TGF-β) in malignant CTCL cells [68, 108]. As noted
above, malignant CTCL cells impair DC maturation and
activation of benign T cells in an IL-10-dependent manner.
Similarly, TGF-β was reported to enhance the malignant T
cells’ ability to inhibit activation of syngenic and allogenic
normal T cells [66–68, 109]. Given the potent immunosup-
pressive capacities of IL-10 and TGF-β, it could be expect-
ed that they would also inhibit the proliferation and cyto-
kine production of the malignant T cells in an autocrine
fashion. However, as observed with the expression of
Fas, malignant T cells in advanced CTCL frequently lack
expression of functional receptors and/or downstream sig-
naling mediators for IL-10 and TGF-β, essentially render-
ing them resistant to the suppressive activities of these
cytokines [82, 86, 110, 111]. Downregulation of Zeb1
has, notably, been shown to confer resistance to TGF-β-
mediated growth inhibition in malignant T cells from adult
T-cell leukemia/lymphoma [112]. These findings exempli-
fy that malignant T cells are able to simultaneously exploit
and escape suppressive mechanisms normally deployed by
the immune system. In a similar fashion, aberrant activa-
tion of Stat3 induces constitutive expression of suppressor
of cytokine signaling-3 (SOCS3), which attenuates the
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effects of several cytokines, including IFN-γ and IFN-α
and, consequently, protects the malignant T cells from
cytok ine -media ted an t i - tumor responses [113] .
Altogether, these data clearly indicates that the malignant
T cells become resistant to immunosuppressive factors
(e.g., dysfunction of Fas-, IL-10-, and TGF-β-signaling
and upregulation of SOCS3) while acquiring the capacity
to inhibit anti-tumor immunity by means of cell contact-
dependent (e.g., CD80, PD-L1, and FasL) and independent
(e.g., Th2 cytokines, IL-10, TGF-β) mechanisms.
The malignant T cells produce autocrine growth
factors that activate pro-oncogenic pathways
The development of a Th2-dominated tumor microenviron-
ment may not merely impede cellular immunity and anti-
tumor responses but also directly fuel the growth of the ma-
lignant T cells. Intriguingly, a recent study by Geskin et al.
provided evidence that the malignant T cells express function-
al receptors for IL-4 and IL-13, and that these cytokines pro-
mote the activation of Stat6 and the proliferation of the tumor
cells [41]. Accordingly, neutralizing antibodies against IL-4
and IL-13, as well as a Stat6 inhibitor, significantly retarded
the proliferation of CD4+ T cells isolated from leukemic
CTCL patients [41]. These findings imply that IL-4 and IL-
13 produced by malignant T cells and benign Th2 cells stim-
ulate the proliferation of the malignant Tcells via activation of
Stat6. Other cytokines that are upregulated in advanced dis-
ease, including IL-15, IL-16, and IL-32, can also augment the
growth of the malignant T cells in an autocrine manner [49,
59, 61, 64, 65, 114]. Of particular interest, IL-15 activates
Stat5 and Stat3 in malignant CTCL cells and has been pro-
posed to contribute to the aberrant activation of these tran-
scription factors [43, 108, 115]. A possible explanation for
the increased expression of IL-15 was provided by a recent
study which documented that the promoter region where Zeb1
can bind and repress transcription of IL-15 is hypermethylated
in malignant T cells from leukemic CTCL patients, resulting
in impaired binding of Zeb1 and unchecked IL-15 expression
[60]. This finding implicates Zeb1 as a putative tumor sup-
pressor of several pathogenic processes in CTCL and suggests
that in patients in whom the ZEB1 gene is not mutated, tumor
suppressive functions of the Zeb1 protein may instead be im-
peded by other mechanisms such as epigenetic modification
of its target DNA. Interestingly, malignant T cells are not the
only source of IL-15 in the lesional skin, as stromal cells also
have the capacity to express IL-15. In particular, epidermal
keratinocytes that become activated by malignant T cells
in vitro and in vivo, have been shown to express IL-15 in situ
in CTCL lesions, indicating that malignant T cells may also
propagate their own proliferation through stimulation of
keratinocytes to produce tumor growth factors such as IL-15
[114, 116]. The fact that transgenic mice overexpressing IL-15
develop a neoplasm that mimics human CTCL reinforces the
idea that IL-15 plays an important role in the disease patho-
genesis [60].
Constitutive activation of the transcription factor NF-κB is,
like dysregulation of the Jak/Stat pathway, a characteristic
feature of malignant CTCL cells and numerous reports have
demonstrated that NF-κB promotes their proliferation and sur-
vival [117, 118]. It was recently reported that IL-32 stimulates
the growth of malignant CTCL cells in a NF-κB-dependent
manner. This finding provides circumstantial evidence that
upregulation of IL-32 during disease progression may contrib-
ute to the constitutive activation of NF-κB [65]. Altoghether,
these data illustrate that in advanced disease the malignant T
cells produce cytokines (e.g., IL-4, IL-13, IL-15 and IL-32),
which can induce chronic activation of key pro-oncogenic
signaling pathways in an autocrine manner. The arsenal of
autocrine growth factors that the malignant T cells are able
to produce is not limited solely to cytokines. For example, it
has been shown that the malignant T cells begin to express
cyclooxygenase-2 (COX-2) in plaque-stage disease, and that
the expression of this protein correlates with in vitro secretion
of its downstream product, prostaglandin E2 (PGE2) [119].
Selective knockdown of COX-2 or PGE2 receptor antagonists
inhibited the spontaneous proliferation of the malignant T
cells in vitro [119]. Furthermore, the COX-2 inhibitor,
celecoxib, reduced tumor growth in a xenograft model of ad-
vancedMF, implicating PGE2 as an autocrine growth factor in
CTCL [120]. PGE2 is known to hamper cell-mediated immu-
nity by various mechanisms. These include inhibition of Th1
cytokine production, repression of CXCL9 and CXCL10 ex-
pression as well as suppression of NK cell- and CD8+ T cell-
mediated cytotoxicity [121]. Hence, analogous to IL-4 and IL-
13, PGE2 may have a dual function in malignant inflamma-
tion by hampering cellular immunity while directly stimulat-
ing the growth of the malignant T cells. In summary, the ma-
lignant T cells appear to gain the capacity to produce a spec-
trum of cytokines and other inflammatory factors that can
promote activation of pro-oncogenic pathways and stimulate
their own expansion.
The malignant T cells foster pro-tumorigenic
inflammation through interactions with stromal
and innate immune cells
In line with the growing Th2-bias and malignant Tcell expres-
sion of factors such as PGE2, IL-10, and high-mobility group
BOX-1 protein (HMGB1), the infiltration of mast cells, eosin-
ophils, and tumor-associated macrophages (TAMs) with an
M2 phenotype, typically increases during CTCL progression
[89, 122–127]. A high degree of infiltration by each of these
immune subsets has been linked to poor prognosis, suggesting
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that the malignant T cells may foster a pro-tumorigenic envi-
ronment by promoting accumulation of granulocytes and
TAMs [122, 123, 127]. Accordingly, Rabenhorst et al. dem-
onstrated that mast cells in CTCL lesions generally exhibit a
degranulated phenotype, and that their numbers correlate with
the microvessel density [122]. Supernatant from activated
mast cells was further able to promote the proliferation of
malignant CTCL cells in vitro, and depletion of mast cells in
a murine T cell lymphoma model inhibited tumor growth,
strongly supporting that mast cells play a pro-tumorigenic role
in CTCL [122]. In a similar manner, eosinophils often display
an activated phenotype and express IL-5 in CTCL skin le-
sions, indicating that they release inflammatory factors into
the tumor microenvironment that may aggravate the disease
[123]. Indeed, accumulation of eosinophils in blood and
lesional skin of CTCL patients has not only been associated
with poor prognosis but also with increased pruritus [6].
Activated eosinophils can, in addition to IL-5, release high
levels of IL-4 and IL-13 as well as angiogenic factors. This
raises the possibility that malignant T cells, through the attrac-
tion and activation of eosinophils, may fuel their own growth
indirectly by boosting neovascularization and a deregulated
Th2 response [128]. Marked infiltration of neutrophils is
only occasionally seen in CTCL, but detection of neutro-
philic dermatoses has been associated with an aggressive
disease course [70, 74]. As already mentioned, L-17A and
IL-17F are expressed in the lesional skin in a subset of
CTCL patients and known to stimulate recruitment of neu-
trophils [62, 70, 71]. High expression of IL-17A has, ac-
cordingly, been associated with neutrophilic infiltration in-
to CTCL lesions; whether it is also the case for IL-17F
remains to be investigated [70]. Malignant T cells derived
from some patients have the capacity to express IL-17A and/
or IL-17F via a Jak3/Stat3/Stat5-dependent mechanism but do
not express the Th17-linage transcription factor, RORc, or
display a characteristic Th17-phenotype [62, 71, 76, 129].
Therefore, expression of IL-17A and IL-17F by the malignant
T cells is probably not reflective of Th17 origin, or acquisition
of a full-fledged Th17 phenotype, but rather a consequence of
dysregulated signaling. Several cell types, including Th17
cells, mast cells and neutrophils are also known to produce
IL-17 cytokines and it is likely that they also provide a signif-
icant source of IL-17A and IL-17F in some lesions.
Accordingly, skin-infiltrating neutrophils and mast cells have
been reported to stain positive for IL-17 in CTCL patients with
neutrophilic dermatoses [72].
The malignant T cells can also exploit monocytes and
dendritic cells to stimulate their expansion. For example,
malignant CTCL cells engage in cell contact-dependent
crosstalk with immature dendritic cells ex vivo that results
in prolonged survival and proliferation of both the malig-
nant T cells and the immature dendritic cells. The malig-
nant T cells have, interestingly, been shown to arrest
dendritic cells in an immature state via secretion of regu-
latory cytokines such as IL-10, indicating that they block
dendritic cell maturation to perpetuate their own growth
and maintain a tolerogenic environment [67, 130].
M2-like TAMs are generally believed to contribute to tu-
morigenesis by promoting angiogenesis, matrix remodeling
and inhibition of adaptive immunity [131]. In agreement with
the notion that the malignant T cells drive the accumulation of
M2-like TAMs during the clinical course of CTCL, M2-like
macrophages were found to be abundant within the tumor
microenvironment, but not in the spleen, in a CTCL mouse
model [126]. Furthermore, effective treatment of CTCL pa-
tients resulting in decreased numbers of tumor cells was
shown to be accompanied by a strong decrease of dermal
TAMs in the lesional skin [127]. TAMs express CCL18 and
MMP9 in CTCL lesions, and clodronate-mediated depletion
of M2-like macrophages in a mouse model of CTCL inhibited
angiogenesis, lymphangiogenesis, and tumor development.
Collectively, these results implicate M2-like TAMs in vascu-
larization, chemotaxis, tissue remodeling, and tumor growth
in CTCL [51, 126, 132].
The malignant T cells also display aberrant release of cy-
tokines and other factors, such as vascular endothelial growth
factor (VEGF), prostaglandins, and lymphotoxins, which pro-
mote activation of endothelial cells and fibroblasts, thereby
stimulating angiogenesis via both direct and indirect mecha-
nisms [62, 70, 71, 81, 119, 133, 134]. For example, the ma-
lignant T cells can trough release of VEGF-A and
lymphotoxin α induce enhanced endothelial sprouting
in vitro and further trigger fibroblast expression of VEGF-C
and angiogenesis in vivo, supporting the concept that the ma-
lignant T cells orchestrate profound changes in the tumor mi-
croenvironment [133, 135]. Indeed, the malignant T cells
strongly impacted skin structure, as well as keratinocyte acti-
vation and proliferation, in an organotypic skin model and a
xenograft CTCL mouse model [116]. Hence, malignant T
cells and their supernatants triggered Jak and MAPK activa-
tion in keratinocytes, downregulation of differentiation
markers such as keratin 10 and involucrin, epidermal
hyperproliferation, disorganized keratinocyte stratification,
and decreased barrier formation, thus mimicking many fea-
tures seen in CTCL lesions [116]. In conclusion, accumulating
evidence indicates that the malignant T cells, via interactions
with stromal and benign immune cells, drive the disease stage-
related inflammatory changes observed in CTCL.
Drugs that stimulate cellular immunity induce
disease regression
As highlighted by the multiple pieces of evidence outlined
above, the shift from a Th1- towards a Th2-dominated tu-
mor-associated inflammatory environment appears to play a
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central role in malignant T cell proliferation and tumor pro-
motion and, at the same time, suppression of cell-mediated
immunity and anti-tumor responses in CTCL. Consistent with
this conclusion, administration of the Th1 cytokines IL-12 and
IFN-γ can induce lesional regression associated with in-
creased numbers of cytotoxic CD8+ T cells in the resolving
skin, and treatment with Toll-like receptor (TLR) agonists that
stimulate cellular immunity have shown clinical efficacy in
CTCL patients [136–144]. For example, a recent clinical
phase 1 trial reported that 75 % of the enrolled CTCL patients
had significant improvement in skin lesions treated topically
with resiquimod gel (TLR-7 and TLR-8 agonist) and 30 %
had clearing of all treated lesions. Some patients even had a
systemic response with improvement of untreated lesions. The
responding patients displayed profoundly decreased numbers
of malignant T cells, and high responses were associated with
recruitment and expansion of benign T cell clones in treated
skin, increased skin T cell effector functions and a trend to-
wards increased NK cell function [144]. The fact that immu-
nomodulatory drugs, which stimulate the cellular immune
system, can induce lesional regression and promote eradica-
tion of the malignant Tcells strongly supports that suppression
of the patients’ cellular immunity represents a critical check-
point for the expansion of the malignant T cells.
Enterotoxin-producing S. aureus may promote
malignant inflammation in CTCL
Aberrant activation of the Jak/Stat pathway seems to be a
central event in the development of malignant inflamma-
tion in CTCL. A significant proportion of patients with
advanced disease, accordingly, display genetic alterations
that directly or indirectly promote constitutive activation
of the Jak/Stat pathway; however, it is unclear what drives
constitutive activation of Jak/Stat signaling in other pa-
tients [19, 21, 24, 25]. Due to a compromised cutaneous
barrier and evolving immune dysfunction, the lesional skin
of CTCL patients is often colonized with enterotoxin-
producing Staphylococcus aureus which represent a major
clinical problem [18, 44, 145–147]. Recent reports have dem-
onstrated that staphylococcal enterotoxins (SE) instigate
crosstalk between the malignant and benign T cells which
leads to increased proliferation, activation of Stat3 and expres-
sion of Stat3-regulated cytokines in the malignant T cells [82,
83, 148]. Consequently, colonization of CTCL lesions with
SE-producing S. aureus may trigger mechanisms that aggra-
vate the disease and promote malignant inflammation. In sup-
port of this theory, a series of smaller studies and case reports
have shown that antibiotic treatment, leading to successful
elimination of S. aureus, is associated with significant clinical
improvement in most colonized patients. Strikingly, in some
patients, antibiotic treatment even resulted in complete clinical
response with no residual skin involvement [18, 145, 146,
149, 150]. Evidence suggests that the malignant T cells are
responsible for the impairment of the skin barrier in CTCL
[116]. This indicates that the malignant T cells both induce
increased susceptibility towards S. aureus and subsequently
exploit the infection to initiate a vicious crosstalk with the
benign T cells which results in activation of pro-oncogenic
pathways. These pathways, in turn, promote the proliferation
of the malignant T cells and their expression of pro-
tumorigenic factors. Although the proposed mechanism is
specific for SE-producing bacteria, it is likely that other infec-
tious agents and extrinsic factors that impact the inflammatory
environment may promote malignant inflammation and dis-
ease progression. On the other hand, it can be speculated that
certain bacteria might be beneficial through their ability to
regulate inflammation or out-compete disease-promoting bac-
teria and, thus, such bacteria may be of therapeutic use in
CTCL if identified.
Malignant inflammation—a hostile takeover
The inflammatory reaction in early indolent disease appears to
be a Bhost^ response directed against the malignant Tcells and
potentially other factors in the tumor microenvironment. Early
inflammation, accordingly, involves CD8+ T cells, Th1 cells
and possibly NK cells in conjunction with cytokines that in-
hibit the expansion of the malignant T cells. However, the
nature and cellular composition of the tumor-associated in-
flammatory environment seem to shift from partly anti-
tumorigenic to pro-tumorigenic during disease progression.
As reviewed above, considerable evidence suggests that the
malignant T cells orchestrate the shift in the inflammatory
microenvironment, enforcing profound changes in the cyto-
kine and chemokine milieu as well as in the composition,
activity and function of most cellular components within the
cutaneous lesions. These changes, in turn, promote tumori-
genic processes, including angiogenesis, lymph-angiogenesis,
tissue remodeling, and tumor growth. The malignant T cells,
thus, appear to perform a Bhostile^ takeover of the lesional
microenvironment, thereby gaining control of the tumor-
associated inflammation to create a setting that facilitates their
own expansion (Fig. 3). The hostile takeover is exemplified
by the tumor cell-mediated induction of (i) malignant growth
factors such as IL-4, IL-13, and IL-15 from non-malignant
cells, (ii) M2-like TAMs, mast cells, and immature dendritic
cells that provide growth and survival signals to the malignant
T cells, and (iii) angiogenesis via stimulation of fibroblasts,
innate immune cells and endothelial cells. In other words,
malignant T cells engage in a Bparasitic^ exploitation of be-
nign immune cells and stromal cells to produce pro-
tumorigenic growth and survival factors. At the same time,
the malignant T cells express immunosuppressive factors that
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foster an immune-privileged tumor site in part by direct inhi-
bition of non-malignant T cells and induction of tolerogenic
macrophages and dendritic cells.
Although it is not known exactly how the malignant T cells
gain the capacity to impose these changes on the inflammatory
environment, a series of recent data suggests that endogenous
changes in the malignant Tcells, including somatic mutations,
somatic copy number variations, and epigenetic deregulation,
may play a critical role [19–25, 60, 151, 152]. Exogenous
factors such as bacterial colonization and infection may also
drive activation of pro-oncogenic mechanisms and inhibit
anti-tumor immunity. In particular, S. aureus and its toxins
appear to possess the ability to stimulate malignant exploita-
tion of non-malignant T cells in a manner which leads to
activation of the Jak/Stat pathway and release of immune
regulatory cytokines such as IL-10. Dysregulation of the
Jak/Stat pathway emerges as a central event in the develop-
ment of malignant inflammation in CTCL and, indeed, evi-
dence from various other cancers also points towards a central
role for certain Stat proteins (e.g., Stat3) in sustaining chronic
inflammation while antagonizing anti-tumor responses [153].
Taken together, these findings suggest that disease progres-
sion is associated with, and at least partly driven by, changes
in the tumor-associated inflammatory environment that are
elicited by the malignant T cells. We suspect that once
established, malignant inflammation will stimulate tumor
growth and foster deepening of the malignant T cell pheno-
type, thereby further enhancing pro-tumorigenic inflammato-
ry processes that may result in a self-perpetuating vicious
circle accelerating cancer progression.
Th2 cell
Th1 cell
CD8 T cell
NK cell
Malignant T cell Fibroblast
Immature DC
Eosinophil
Mast cell
Keratinocyte M2-like TAM Endothelial cell
A B C
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Fig. 3 Amodel of malignant inflammation. a–c Schematic illustration of
progression from a early indolent CTCL with few malignant T cells b, c
to more advanced disease increasingly dominated by Th2-biased
inflammation and malignant T cells. d In early indolent disease, the
expansion of the malignant T cells is kept in check by a cellular anti-
tumor immune response involving CD8+ Tcells, Th1 cells, and NK cells.
e In time, malignant T cell endogenous (e.g., genetic and epigenetic
alterations) and exogenous (e.g., irradiation, toxins, microbes,
chemicals, drugs) events can enable the malignant T cells to take control
of the tumor microenvironment, thereby inhibiting the cellular anti-tumor
immune response while stimulating the accumulation and/or activation of
certain types of benign immune cells and stromal cells (f) that produce
pro-tumorigenic factors which directly or indirectly foster the survival
and expansion of the malignant T cells
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Malignant inflammation in solid cancers
The importance of the tumor-associated inflammatory envi-
ronment is now more and more recognized in many solid
tumor contexts and models [154–156]. In particular, a bias
in Th1/Th2 cell ratio and/or changes in the circulating cyto-
kine profile are increasingly associated with many solid tumor
types, including prostate, oral, ovarian, pancreatic, cervical,
colorectal, and breast cancers [157–165]. There is also evi-
dence that the tumor-immune environment influences thera-
peutic responses. Breast cancer is, for example, known to har-
bor a pro-inflammatory milieu often associated with obesity
and increased PGE2 levels [166]. However, patients harboring
an increased number of Th1 relative to Th2 cells typically
experience superior outcomes [159]. Related to this, a loss of
anti-HER2 Th1 cells in breast cancer correlates with poor re-
sponse to HER2-targetted therapies [161]. The mechanisms
underpinning the shift from a Th1 to a Th2 response in non-
CTCL cancers are subject of intense research. Recently, it has
been shown that polycomb repressive complex mediates
epigenetic silencing of the Th1 chemokines, CXCL9 and
CXCL10, in ovarian and colorectal cancers, thereby re-
ducing recruitment of CD8+ T cells [162, 165]. Ovarian
and colorectal cancer patients with increased numbers of
intra-tumoral CD8+ T cells or Th1 cells consistently ex-
perience better outcomes [158, 162, 165]. Therefore,
epigenetic-targeting therapies may potentiate the sensitiv-
ity to immuno-therapies by modulating the inflammatory
environment. As indicated by these examples, malignant
inflammation, as defined here, may also be of importance
in solid cancers, suggesting that some of the mechanisms
described in CTCL may be of general relevance in cancer.
Conclusions
In conclusion, recent as well as earlier data support our hy-
pothesis that the malignant T cells are key drivers of the in-
flammatory changes observed during disease progression in
CTCL, and that these changes inhibit anti-tumor immunity
while promoting tumor growth. If correct, this hypothesis pre-
dicts that the most effective treatment of progressive and ad-
vanced disease should rationally combine therapeutics that
directly target the malignant Tcells with drugs that (i) enhance
cellular immunity, (ii) neutralize immune evasive mecha-
nisms, (iii) inhibit the pro-tumorigenic environment, and (iv)
eliminate pro-oncogenic bacteria such as enterotoxin-
producing S. aureus in infected patients. Such combined ther-
apeutic strategies would perhaps give a realistic hope for ef-
fective treatment, or even a cure, of this devastating disease.
Acknowledgments This work was supported by research funding from
the Danish Research Council, the Novo Nordic Foundation, the Novo
Nordic Foundation Tandem program, the Lundbeck Foundation, the
Danish Cancer Society (Kræftens Bekæmpelse), and the Danish Cancer
Society and TV2 BKnæk-Cancer-Program^. TKwas further supported by
a Sapera Aude Talent Grant (DFF-4092-00122) from the Danish Council
for Independent Research.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classi-
fication for cutaneous lymphomas. Blood 105:3768–3785
2. Scarisbrick JJ, KimYH,Whittaker SJ et al (2014) Prognostic factors,
prognostic indices and staging in mycosis fungoides and Sezary
syndrome: where are we now? Br J Dermatol 170:1226–1236
3. Wilcox RA (2016) Cutaneous T-cell lymphoma: 2016 update on
diagnosis, risk-stratification, and management. Am J Hematol 91:
151–165
4. Agar NS, Wedgeworth E, Crichton S et al (2010) Survival out-
comes and prognostic factors in mycosis fungoides/Sezary syn-
drome: validation of the revised International Society for
Cutaneous Lymphomas/European Organisation for Research and
Treatment of Cancer staging proposal. J Clin Oncol 28:4730–4739
5. Scarisbrick JJ, Prince HM, Vermeer MH et al (2015) Cutaneous
lymphoma international consortium study of outcome in advanced
stages of mycosis fungoides and Sezary syndrome: effect of spe-
cific prognostic markers on survival and development of a prog-
nostic model. J Clin Oncol 33:3766–3773
6. Diwan AH, Prieto VG, Herling M et al (2005) Primary Sezary
syndrome commonly shows low-grade cytologic atypia and an
absence of epidermotropism. Am J Clin Pathol 123:510–515
7. Ferenczi K, Fuhlbrigge RC, Pinkus J et al (2002) Increased CCR4
expression in cutaneous T cell lymphoma. J Invest Dermatol 119:
1405–1410
8. Kallinich T, Muche JM, Qin S et al (2003) Chemokine receptor
expression on neoplastic and reactive Tcells in the skin at different
stages of mycosis fungoides. J Invest Dermatol 121:1045–1052
9. Campbell JJ, Clark RA, Watanabe R et al (2010) Sezary syndrome
and mycosis fungoides arise from distinct T-cell subsets: a biologic
rationale for their distinct clinical behaviors. Blood 116:767–771
10. Sugaya M, Morimura S, Suga H et al (2015) CCR4 is expressed
on infiltrating cells in lesional skin of early mycosis fungoides and
atopic dermatitis. J Dermatol 42:613–615
11. Fujita Y, Abe R, Sasaki M et al (2006) Presence of circulating
CCR10+ T cells and elevated serum CTACK/CCL27 in the early
stage of mycosis fungoides. Clin Cancer Res 12:2670–2675
12. Lu D, Duvic M, Medeiros LJ et al (2001) The T-cell chemokine
receptor CXCR3 is expressed highly in low-grade mycosis
fungoides. Am J Clin Pathol 115:413–421
13. Tensen CP, Vermeer MH, van der Stoop PM et al (1998)
Epidermal interferon-gamma inducible protein-10 (IP-10) and
Semin Immunopathol
monokine induced by gamma-interferon (Mig) but not IL-8
mRNA expression is associated with epidermotropism in cutane-
ous T cell lymphomas. J Invest Dermatol 111:222–226
14. Miyagaki T, Sugaya M (2014) Immunological milieu in mycosis
fungoides and Sezary syndrome. J Dermatol 41:11–18
15. Krejsgaard T, Odum N, Geisler C et al (2012) Regulatory T cells
and immunodeficiency in mycosis fungoides and Sezary syn-
drome. Leukemia 26:424–432
16. Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Demographic
patterns of cutaneous T-cell lymphoma incidence in Texas based
on two different cancer registries. Cancer Med 4:1440–1447
17. Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Identification of
geographic clustering and regions spared by cutaneous T-cell lym-
phoma in Texas using 2 distinct cancer registries. Cancer 121:
1993–2003
18. Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2013)
Bacterial toxins fuel disease progression in cutaneous T-cell lym-
phoma. Toxins (Basel) 5:1402–1421
19. Choi J, Goh G, Walradt T et al (2015) Genomic landscape of
cutaneous T cell lymphoma. Nat Genet 47:1011–1019
20. Ungewickell A, Bhaduri A, Rios E et al (2015) Genomic analysis
of mycosis fungoides and Sezary syndrome identifies recurrent
alterations in TNFR2. Nat Genet 47:1056–1060
21. Kiel MJ, Sahasrabuddhe AA, Rolland DC et al (2015) Genomic
analyses reveal recurrent mutations in epigenetic modifiers and the
JAK-STAT pathway in Sezary syndrome. Nat Commun 6
22. Wang L, Ni X, Covington KR et al (2015) Genomic profiling of
Sezary syndrome identifies alterations of key T cell signaling and
differentiation genes. Nat Genet 47:1426–1434
23. da Silva Almeida AC, Abate F, Khiabanian H et al (2015) The
mutational landscape of cutaneous T cell lymphoma and Sezary
syndrome. Nat Genet 47:1465–1470
24. WoollardWJ, Pullabhatla V, Lorenc A et al (2016) Candidate driver
genes in Sezary syndrome: frequent perturbations of genes involved
in genome maintenance and DNA repair. Blood 127:3387–3397
25. McGirt LY, Jia P, Baerenwald DA et al (2015) Whole-genome
sequencing reveals oncogenic mutations in mycosis fungoides.
Blood 126:508–519
26. Belloni B, Johansen N, Glass LF et al (2012) Recent advances in
the management of cutaneous lymphomas. Semin Oncol 39:150–
162
27. Kim EJ, Hess S, Richardson SK et al (2005) Immunopathogenesis
and therapy of cutaneous Tcell lymphoma. J Clin Invest 115:798–
812
28. Wood GS, Edinger A, Hoppe RT et al (1994) Mycosis fungoides
skin lesions contain CD8+ tumor-infiltrating lymphocytes ex-
pressing an activated, MHC-restricted cytotoxic T-lymphocyte
phenotype. J Cutan Pathol 21:151–156
29. Asadullah K, Friedrich M, Docke WD et al (1997) Enhanced
expression of T-cell activation and natural killer cell antigens in-
dicates systemic anti-tumor response in early primary cutaneous
T-cell lymphoma. J Invest Dermatol 108:743–747
30. Bagot M, Echchakir H, Mami-Chouaib F et al (1998) Isolation of
tumor-specific cytotoxic CD4+ and CD4 + CD8dim + T-cell
clones infiltrating a cutaneous T-cell lymphoma. Blood 91:
4331–4341
31. Echchakir H, Bagot M, Dorothee G et al (2000) Cutaneous T cell
lymphoma reactive CD4+ cytotoxic T lymphocyte clones display
a Th1 cytokine profile and use a fas-independent pathway for
specific tumor cell lysis. J Invest Dermatol 115:74–80
32. Vermeer MH, van DoomR, Dukers D et al (2001) CD8+ Tcells in
cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas
ligand, and killing inhibitory receptors and their relationship with
clinical behavior. J Clin Oncol 19:4322–4329
33. Hsi AC, Lee SJ, Rosman IS et al (2015) Expression of helper T
cell master regulators in inflammatory dermatoses and primary
cutaneous T-cell lymphomas: diagnostic implications. J Am
Acad Dermatol 72:159–167
34. Hoppe RT, Medeiros LJ, Warnke RA et al (1995) CD8-positive
tumor-infiltrating lymphocytes influence the long-term survival of
patients with mycosis fungoides. J Am Acad Dermatol 32:448–
453
35. Berger CL, Wang N, Christensen I et al (1996) The immune re-
sponse to class I-associated tumor-specific cutaneous T-cell lym-
phoma antigens. J Invest Dermatol 107:392–397
36. Bouaziz JD, Ortonne N, Giustiniani J et al (2005) Circulating
natural killer lymphocytes are potential cytotoxic effectors against
autologous malignant cells in Sezary syndrome patients. J Invest
Dermatol 125:1273–1278
37. Abeni D, Frontani M, Sampogna F et al (2005) Circulating CD8+
lymphocytes, white blood cells, and survival in patients with my-
cosis fungoides. Br J Dermatol 153:324–330
38. Vowels BR, Lessin SR, Cassin M et al (1994) Th2 cytokine
mRNA expression in skin in cutaneous T-cell lymphoma. J
Invest Dermatol 103:669–673
39. Papadavid E, Economidou J, Psarra A et al (2003) The relevance
of peripheral blood T-helper 1 and 2 cytokine pattern in the eval-
uation of patients with mycosis fungoides and Sezary syndrome.
Br J Dermatol 148:709–718
40. Hahtola S, Tuomela S, Elo L et al (2006) Th1 response and cyto-
toxicity genes are down-regulated in cutaneous T-cell lymphoma.
Clin Cancer Res 12:4812–4821
41. Geskin LJ, Viragova S, Stolz DB et al (2015) Interleukin-13 is
overexpressed in cutaneous T-cell lymphoma cells and regulates
their proliferation. Blood 125:2798–2805
42. Johnson VE, Vonderheid EC, Hess AD et al (2014) Genetic
markers associated with progression in early mycosis fungoides.
J Eur Acad Dermatol Venereol 28:1431–1435
43. Netchiporouk E, Litvinov IV, Moreau L et al (2014) Deregulation
in STAT signaling is important for cutaneous T-cell lymphoma
(CTCL) pathogenesis and cancer progression. Cell Cycle 13:
3331–3335
44. Axelrod PI, Lorber B, Vonderheid EC (1992) Infections compli-
cating mycosis fungoides and Sezary syndrome. JAMA 267:
1354–1358
45. Miyagaki T, SugayaM, SugaH et al (2012) Low herpesvirus entry
mediator (HVEM) expression on dermal fibroblasts contributes to
a Th2-dominant microenvironment in advanced cutaneous T-cell
lymphoma. J Invest Dermatol 132:1280–1289
46. Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the
orchestrators: chemokines in control of Tcell traffic. Nat Immunol
9:970–980
47. Kakinuma T, Sugaya M, Nakamura K et al (2003) Thymus and
activation-regulated chemokine (TARC/CCL17) in mycosis
fungoides: serum TARC levels reflect the disease activity of my-
cosis fungoides. J Am Acad Dermatol 48:23–30
48. Miyagaki T, Sugaya M, Suga H et al (2013) Increased CCL18
expression in patients with cutaneous T-cell lymphoma: associa-
tion with disease severity and prognosis. J Eur Acad Dermatol
Venereol 27:e60–e67
49. Tuzova M, Richmond J, Wolpowitz D et al (2015) CCR4+ T cell
recruitment to the skin in mycosis fungoides: potential contribu-
tions by thymic stromal lymphopoietin and interleukin-16. Leuk
Lymphoma 56:440–449
50. Miyagaki T, Sugaya M, Fujita H et al (2010) Eotaxins and CCR3
interaction regulates the Th2 environment of cutaneous T-cell
lymphoma. J Invest Dermatol 130:2304–2311
51. Gunther C, Zimmermann N, Berndt N et al (2011) Up-regulation
of the chemokine CCL18 by macrophages is a potential immuno-
modulatory pathway in cutaneous T-cell lymphoma. Am J Pathol
179:1434–1442
Semin Immunopathol
52. Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expres-
sion of the eotaxin receptor CCR3 by human T helper 2 cells.
Science 277:2005–2007
53. Islam SA, Ling MF, Leung J et al (2013) Identification of human
CCR8 as a CCL18 receptor. J Exp Med 210:1889–1898
54. Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase 1/2 study
of mogamulizumab, a defucosylated anti-CCR4 antibody, in pre-
viously treated patients with cutaneous T-cell lymphoma. Blood
125:1883–1889
55. Miyagaki T, Sugaya M, Suga H et al (2011) IL-22, but not IL-17,
dominant environment in cutaneous T-cell lymphoma. Clin
Cancer Res 17:7529–7538
56. Ito M, Teshima K, Ikeda S et al (2014) Micro RNA-150 inhibits
tumor invasion and metastasis by targeting the chemokine recep-
tor CCR6, in advanced cutaneous T-cell lymphoma. Blood 123:
1499–1511
57. Ikeda S, Kitadate A, Ito M et al (2016) Disruption of CCL20-
CCR6 interaction inhibits metastasis of advanced cutaneous T-
cell lymphoma. Oncotarget 7:13563–13574
58. Asadullah K, DockeWD, Haeussler A et al (1996) Progression of
mycosis fungoides is associated with increasing cutaneous expres-
sion of interleukin-10 mRNA. J Invest Dermatol 107:833–837
59. Asadullah K, Haeussler-Quade A, Gellrich S et al (2000) IL-15
and IL-16 overexpression in cutaneous T-cell lymphomas: stage-
dependent increase in mycosis fungoides progression. Exp
Dermatol 9:248–251
60. Mishra A, La PK, Kwiatkowski S et al (2016) Mechanism, con-
sequences and therapeutic targeting of abnormal IL-15 signaling
in cutaneous T-cell lymphoma. Cancer Discov 6:986–1005
61. Blaschke V, Reich K, Middel P et al (1999) Expression of the
CD4+ cell-specific chemoattractant interleukin-16 in mycosis
fungoides. J Invest Dermatol 113:658–663
62. Krejsgaard T, Litvinov IV, Wang Y et al (2013) Elucidating the
role of interleukin-17F in cutaneous T-cell lymphoma. Blood 122:
943–950
63. van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-
analysis of gene expression data identifies a molecular signature
characteristic for tumor-stage mycosis fungoides. J Invest
Dermatol 132:2050–2059
64. Ohmatsu H, Humme D, Gulati N et al (2014) IL32 is progressive-
ly expressed in mycosis fungoides independent of helper T-cell 2
and helper T-cell 9 polarization. Cancer Immunol Res 2:890–900
65. Suga H, Sugaya M, Miyagaki T et al (2014) The role of IL-32 in
cutaneous T-cell lymphoma. J Invest Dermatol 134:1428–1435
66. Rook AH, Kubin M, Cassin M et al (1995) IL-12 reverses cyto-
kine and immune abnormalities in Sezary syndrome. J Immunol
154:1491–1498
67. Wilcox RA, Wada DA, Ziesmer SC et al (2009) Monocytes pro-
mote tumor cell survival in T-cell lymphoproliferative disorders
and are impaired in their ability to differentiate into mature den-
dritic cells. Blood 114:2936–2944
68. Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al (2008) Malignant
Tregs express low molecular splice forms of FOXP3 in Sezary
syndrome. Leukemia 22:2230–2239
69. Richmond J, Tuzova M, Parks A et al (2011) Interleukin-16 as a
marker of Sezary syndrome onset and stage. J Clin Immunol 31:
39–50
70. Ciree A, Michel L, Camilleri-Broet S et al (2004) Expression and
activity of IL-17 in cutaneous T-cell lymphomas (mycosis
fungoides and Sezary syndrome. Int J Cancer 112:113–120
71. Krejsgaard T, Ralfkiaer U, Clasen-Linde E et al (2011)
Malignant cutaneous T-cell lymphoma cells express IL-17
utilizing the Jak3/Stat 3 signaling pathway. J Invest
Dermatol 131:1331–1338
72. Fontao L, Brembilla NC, Masouye I et al (2012) Interleukin-17
expression in neutrophils and Th17 cells in cutaneous T-cell
lymphoma associated with neutrophilic infiltrate of the skin. Br J
Dermatol 166:687–689
73. Wolk K, Mitsui H, Witte K et al (2014) Deficient cutaneous anti-
bacterial competence in cutaneous T-cell lymphomas: role of Th2-
mediated biased Th17 function. Clin Cancer Res 20:5507–5516
74. Franck N, Carlotti A, Gorin I et al (2005) Mycosis fungoides-type
cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch
Dermatol 141:353–356
75. Nielsen M, Nissen MH, Gerwien J et al (2002) Spontaneous
interleukin-5 production in cutaneous T-cell lymphoma lines is
mediated by constitutively activated stat 3. Blood 99:973–977
76. Guenova E, Watanabe R, Teague JE et al (2013) TH2 cytokines
frommalignant cells suppress TH1 responses and enforce a global
TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer
Res 19:3755–3763
77. Zhang Q, Nowak I, Vonderheid EC et al (1996) Activation of Jak/
STAT proteins involved in signal transduction pathway mediated
by receptor for interleukin 2 in malignant T lymphocytes derived
from cutaneous anaplastic large T-cell lymphoma and Sezary syn-
drome. Proc Natl Acad Sci USA 93:9148–9153
78. Zhang Q, Raghunath PN, Vonderheid E et al (2000) Lack of
phosphotyrosine phosphatase SHP-1 expression in malignant T-
cell lymphoma cells results from methylation of the SHP-1 pro-
moter. Am J Pathol 157:1137–1146
79. Qin JZ, Kamarashev J, Zhang CL et al (2001) Constitutive and
interleukin-7- and interleukin-15-stimulated DNA binding of
STAT and novel factors in cutaneous T cell lymphoma cells. J
Invest Dermatol 117:583–589
80. Sommer VH, Clemmensen OJ, Nielsen O et al (2004) In vivo
activation of STAT3 in cutaneous T-cell lymphoma. Evidence
for an antiapoptotic function of STAT3. Leukemia 18:1288–1295
81. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al (2006) Jak3-
and JNK-dependent vascular endothelial growth factor expression
in cutaneous T-cell lymphoma. Leukemia 20:1759–1766
82. Krejsgaard T, Willerslev-Olsen A, Lindahl LM et al (2014)
Staphylococcal enterotoxins stimulate lymphoma-associated im-
mune dysregulation. Blood 124:761–770
83. Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2016)
Staphylococcal enterotoxin a (SEA) stimulates STAT3 activation
and IL-17 expression in cutaneous T-cell lymphoma. Blood 127:
1287–1296
84. Litvinov IV, Cordeiro B, Fredholm S et al (2014) Analysis of
STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients
and patient-derived cell lines. Cell Cycle 13:2975–2982
85. Nebozhyn M, Loboda A, Kari L et al (2006) Quantitative PCR on
5 genes reliably identifies CTCL patients with 5 % to 99 % circu-
lating tumor cells with 90 % accuracy. Blood 107:3189–3196
86. van Doom R, Dijkman R, MH Vet al (2004) Aberrant expression
of the tyrosine kinase receptor EphA4 and the transcription factor
twist in Sezary syndrome identified by gene expression analysis.
Cancer Res 64:5578–5586
87. Kopp KL, Ralfkiaer U, Gjerdrum LM et al (2013) STAT5-
mediated expression of oncogenic miR-155 in cutaneous T-cell
lymphoma. Cell Cycle 12:1939–1947
88. Litvinov IV, Pehr K, Sasseville D (2013) Connecting the dots in
cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant
T cell proliferation via miR-155. Cell Cycle 12:2172–2173
89. Furudate S, Fujimura T, Kakizaki A et al (2016) Tumor-associated
M2 macrophages in mycosis fungoides acquire immunomodula-
tory function by interferon alpha and interferon gamma. J
Dermatol Sci 83:182–189
90. Bao L, Shi VY, Chan LS (2012) IL-4 regulates chemokine CCL26
in keratinocytes through the Jak1, 2/stat 6 signal transduction
pathway: implication for atopic dermatitis. Mol Immunol 50:91–
97
Semin Immunopathol
91. Fujita H, Asahina A, Sugaya M et al (2005) Differential produc-
tion of Th1- and Th2-type chemokines bymouse Langerhans cells
and splenic dendritic cells. J Invest Dermatol 124:343–350
92. Ohta K, Shigeishi H, Taki M et al (2008) Regulation of CXCL9/
10/11 in oral keratinocytes and fibroblasts. J Dent Res 87:1160–
1165
93. Kodelja V,Muller C, Politz O et al (1998) Alternative macrophage
activation-associated CC-chemokine-1, a novel structural homo-
logue of macrophage inflammatory protein-1 alpha with a Th2-
associated expression pattern. J Immunol 160:1411–1418
94. Antonelli A, Ferrari SM, Giuggioli D et al (2014) Chemokine (C-
X-C motif) ligand (CXCL)10 in autoimmune diseases.
Autoimmun Rev 13:272–280
95. Zhang Q, Wang HY, Wei F et al (2014) Cutaneous T cell lympho-
ma expresses immunosuppressive CD80 (B7-1) cell surface pro-
tein in a STAT5-dependent manner. J Immunol 192:2913–2919
96. Chen L, Flies DB (2013) Molecular mechanisms of T cell co-
stimulation and co-inhibition. Nat Rev Immunol 13:227–242
97. Samimi S, Benoit B, Evans K et al (2010) Increased programmed
death-1 expression on CD4+ T cells in cutaneous T-cell lympho-
ma: implications for immune suppression. Arch Dermatol 146:
1382–1388
98. AbrahamRM, ZhangQ, OdumN et al (2011) The role of cytokine
signaling in the pathogenesis of cutaneous T-cell lymphoma.
Cancer Biol Ther 12:1019–1022
99. Wilcox RA, Feldman AL, Wada DA et al (2009) B7-H1 (PD-L1,
CD274) suppresses host immunity in T-cell lymphoproliferative
disorders. Blood 114:2149–2158
100. Kantekure K, Yang Y, Raghunath P et al (2012) Expression pat-
terns of the immunosuppressive proteins PD-1/CD279 and PD-
L1/CD274 at different stages of cutaneous T-cell lymphoma/
mycosis fungoides. Am J Dermatopathol 34:126–128
101. Munir S, Andersen GH, Woetmann A et al (2013) Cutaneous T
cell lymphoma cells are targets for immune checkpoint ligand PD-
L1-specific, cytotoxic T cells. Leukemia 27:2251–2253
102. Ni X, Hazarika P, Zhang C et al (2001) Fas ligand expression by
neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic
T lymphocytes in mycosis fungoides: a potential mechanism of
tumor immune escape? Clin Cancer Res 7:2682–2692
103. Ni X, Zhang C, Talpur R et al (2005) Resistance to activation-
induced cell death and bystander cytotoxicity via the fas/fas ligand
pathway are implicated in the pathogenesis of cutaneous T cell
lymphomas. J Invest Dermatol 124:741–750
104. Zoi-Toli O, Vermeer MH, De VE et al (2000) Expression of Fas
and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL):
association between lack of Fas expression and aggressive types of
CTCL. Br J Dermatol 143:313–319
105. Nagasawa T, Takakuwa T, Takayama H et al (2004) Fas gene
mutations in mycosis fungoides: analysis of laser capture-
microdissected specimens from cutaneous lesions. Oncology 67:
130–134
106. Contassot E, Kerl K, Roques S et al (2008) Resistance to FasL and
tumor necrosis factor-related apoptosis-inducing ligand-mediated
apoptosis in Sezary syndrome T-cells associated with impaired
death receptor and FLICE-inhibitory protein expression. Blood
111:4780–4787
107. Esmailzadeh S, Huang Y, MW S et al (2015) BIN1 tumor sup-
pressor regulates Fas/Fas ligand-mediated apoptosis through c-
FLIP in cutaneous T-cell lymphoma. Leukemia 29:1402–1413
108. Kasprzycka M, Zhang Q, Witkiewicz A et al (2008) Gamma c-
signaling cytokines induce a regulatory T cell phenotype in malig-
nant CD4+ T lymphocytes. J Immunol 181:2506–2512
109. Chung JS, Shiue LH, Duvic M et al (2011) Sezary syndrome cells
overexpress syndecan-4 bearing distinct heparan sulfate moieties
that suppress T-cell activation by binding DC-HIL and trapping
TGF-beta on the cell surface. Blood 117:3382–3390
110. Kadin ME, Cavaille-Coll MW, Gertz R et al (1994) Loss of recep-
tors for transforming growth factor beta in human T-cell malignan-
cies. Proc Natl Acad Sci USA 91:6002–6006
111. Dulmage BO, Geskin LJ (2013) Lessons learned from gene ex-
pression profiling of cutaneous T-cell lymphoma. Br J Dermatol
169:1188–1197
112. Nakahata S, Yamazaki S, Nakauchi H et al (2010) Downregulation
of ZEB1 and overexpression of Smad 7 contribute to resistance to
TGF-beta 1-mediated growth suppression in adult T-cell leukemia/
lymphoma. Oncogene 29:4157–4169
113. Brender C, Lovato P, Sommer VH et al (2005) Constitutive
SOCS-3 expression protects T-cell lymphoma against growth in-
hibition by IFNalpha. Leukemia 19:209–213
114. Dobbeling U, Dummer R, Laine E et al (1998) Interleukin-15 is an
autocrine/paracrine viability factor for cutaneous T-cell lymphoma
cells. Blood 92:252–258
115. Marzec M, Halasa K, Kasprzycka M et al (2008) Differential
effects of interleukin-2 and interleukin-15 versus interleukin-21
on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:
1083–1091
116. Thode C, Woetmann A, Wandall HH et al (2015) Malignant T
cells secrete galectins and induce epidermal hyperproliferation
and disorganized stratification in a skin model of cutaneous T-
cell lymphoma. J Invest Dermatol 135:238–246
117. Izban KF, Ergin M, Qin JZ et al (2000) Constitutive expression of
NF-kappa B is a characteristic feature of mycosis fungoides: im-
plications for apoptosis resistance and pathogenesis. Hum Pathol
31:1482–1490
118. Sors A, Jean-Louis F, Pellet C et al (2006) Down-regulating con-
stitutive activation of the NF-kappa B canonical pathway over-
comes the resistance of cutaneous T-cell lymphoma to apoptosis.
Blood 107:2354–2363
119. Kopp KL, Kauczok CS, Lauenborg B et al (2010) COX-2-
dependent PGE(2) acts as a growth factor in mycosis fungoides
(MF). Leukemia 24:1179–1185
120. Kopp KL, Dabelsteen S, Krejsgaard T et al (2010) COX-2 is a
novel target in therapy of mycosis fungoides. Leukemia 24:2127–
2129
121. Kalinski P (2012) Regulation of immune responses by prostaglan-
din E2. J Immunol 188:21–28
122. Rabenhorst A, Schlaak M, Heukamp LC et al (2012) Mast cells
play a protumorigenic role in primary cutaneous lymphoma.
Blood 120:2042–2054
123. Ionescu MA, Rivet J, Daneshpouy M et al (2005) In situ eosino-
phil activation in 26 primary cutaneous T-cell lymphomas with
blood eosinophilia. J Am Acad Dermatol 52:32–39
124. Kural YB, Su O,OnsunN et al (2010) Atopy, IgE and eosinophilic
cationic protein concentration, specific IgE positivity, eosinophil
count in cutaneous T cell lymphoma. Int J Dermatol 49:390–395
125. Fredholm S, Gjerdrum LM, Willerslev-Olsen A et al (2014)
STAT3 activation and infiltration of eosinophil granulocytes in
mycosis fungoides. Anticancer Res 34:5277–5286
126. Wu X, Schulte BC, Zhou Y et al (2014) Depletion of M2-like
tumor-associated macrophages delays cutaneous T-cell lymphoma
development in vivo. J Invest Dermatol 134:2814–2822
127. SugayaM,Miyagaki T, Ohmatsu H et al (2012) Association of the
numbers of CD163(+) cells in lesional skin and serum levels of
soluble CD163 with disease progression of cutaneous T cell lym-
phoma. J Dermatol Sci 68:45–51
128. Davoine F, Lacy P (2014) Eosinophil cytokines, chemokines, and
growth factors: emerging roles in immunity. Front Immunol 5
129. Ehrentraut S, Schneider B, Nagel S et al (2016) Th17 cytokine
differentiation and loss of plasticity after SOCS1 inactivation in a
cutaneous T-cell lymphoma. Oncotarget. doi:10.18632
/oncotarget. 9077
Semin Immunopathol
130. Berger CL, Hanlon D, Kanada D et al (2002) The growth of
cutaneous T-cell lymphoma is stimulated by immature dendritic
cells. Blood 99:2929–2939
131. Komohara Y, Jinushi M, TakeyaM (2014) Clinical significance of
macrophage heterogeneity in human malignant tumors. Cancer
Sci 105:1–8
132. Vacca A, Moretti S, Ribatti D et al (1997) Progression of mycosis
fungoides is associated with changes in angiogenesis and expres-
sion of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:
1685–1692
133. Lauenborg B, Christensen L, Ralfkiaer U et al (2015) Malignant T
cells express lymphotoxin alpha and drive endothelial activation in
cutaneous T cell lymphoma. Oncotarget 6:15235–15249
134. Pileri A, Agostinelli C, Righi S et al (2015) Vascular endothelial
growth factor a (VEGFA) expression in mycosis fungoides.
Histopathology 66:173–181
135. Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C et al (2013)
Vascular endothelial growth factor receptor-3 expression in myco-
sis fungoides. Leuk Lymphoma 54:819–826
136. Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy
of cutaneous T-cell lymphoma induces lesion regression and cy-
totoxic T-cell responses. Blood 94:902–908
137. Suchin KR, Junkins-Hopkins JM, Rook AH (2002) Treatment of
stage IA cutaneous T-cell lymphoma with topical application of
the immune response modifier imiquimod. Arch Dermatol 138:
1137–1139
138. Dummer R, Hassel JC, Fellenberg F et al (2004) Adenovirus-
mediated intralesional interferon-gamma gene transfer induces tu-
mor regressions in cutaneous lymphomas. Blood 104:1631–1638
139. Wysocka M, Benoit BM, Newton S et al (2004) Enhancement of
the host immune responses in cutaneous T-cell lymphoma by CpG
oligodeoxynucleotides and IL-15. Blood 104:4142–4149
140. Duvic M, Sherman ML, Wood GS et al (2006) A phase II open-
label study of recombinant human interleukin-12 in patients with
stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55:
807–813
141. Wysocka M, Newton S, Benoit BM et al (2007) Synthetic
imidazoquinolines potently and broadly activate the cellular im-
mune response of patients with cutaneous T-cell lymphoma: syn-
ergy with interferon-gamma enhances production of interleukin-
12. Clin Lymphoma Myeloma 7:524–534
142. Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-
like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with
treatment-refractory, cutaneous T-cell lymphoma. J Am Acad
Dermatol 63:975–983
143. Accart N, Urosevic-Maiwald M, Dummer R et al (2013)
Lymphocytic infiltration in the cutaneous lymphoma microenvi-
ronment after injection of TG 1042. J Transl Med 11:226
144. Rook AH, Gelfand JM, Wysocka M et al (2015) Topical
resiquimod can induce disease regression and enhance T-cell ef-
fector functions in cutaneous T-cell lymphoma. Blood 126:1452–
1461
145. Jackow CM, Cather JC, Hearne V et al (1997) Association of
erythrodermic cutaneous T-cell lymphoma, superantigen-positive
Staphylococcus aureus, and oligoclonal T-cell receptor V beta
gene expansion. Blood 89:32–40
146. Talpur R, Bassett R, Duvic M (2008) Prevalence and treatment of
Staphylococcus aureus colonization in patients with mycosis
fungoides and Sezary syndrome. Br J Dermatol 159:105–112
147. Nguyen V, Huggins RH, Lertsburapa T et al (2008) Cutaneous T-
cell lymphoma and Staphylococcus aureus colonization. J Am
Acad Dermatol 59:949–952
148. Woetmann A, Lovato P, Eriksen KWet al (2007) Nonmalignant T
cells stimulate growth of T-cell lymphoma cells in the presence of
bacterial toxins. Blood 109:3325–3332
149. Tokura Y, Yagi H, Ohshima A et al (1995) Cutaneous colonization
with staphylococci influences the disease activity of Sezary syn-
drome: a potential role for bacterial superantigens. Br J Dermatol
133:6–12
150. Duvic M, Hester JP, Lemak NA (1996) Photopheresis therapy for
cutaneous T-cell lymphoma. J Am Acad Dermatol 35:573–579
151. van Doom R, Slieker RC, Boonk SE et al (2016) Epigenomic
analysis of Sezary syndrome defines patterns of aberrant DNA
methylation and identifies diagnostic markers. J Invest Dermatol
136:1876–1884
152. van Doom R, Zoutman WH, Dijkman R et al (2005) Epigenetic
profiling of cutaneous T-cell lymphoma: promoter hypermethyla-
tion of multiple tumor suppressor genes including BCL7a,
PTPRG, and p 73. J Clin Oncol 23:3886–3896
153. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and
immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809
154. Cheah MT, Chen JY, Sahoo D et al (2015) CD14-expressing can-
cer cells establish the inflammatory and proliferative tumor micro-
environment in bladder cancer. Proc Natl Acad Sci USA 112:
4725–4730
155. Ma X, Aoki T, Tsuruyama T et al (2015) Definition of prostaglan-
din E2-EP2 signals in the colon tumor microenvironment that
amplify inflammation and tumor growth. Cancer Res 75:2822–
2832
156. Lou Y, Diao L, Cuentas ER et al (2016) Epithelial-mesenchymal
transition is associated with a distinct tumor microenvironment
including elevation of inflammatory signals and multiple immune
checkpoints in lung adenocarcinoma. Clin Cancer Res 22:3630–
3642
157. Bais AG, Beckmann I, Lindemans J et al (2005) A shift to a
peripheral Th2-type cytokine pattern during the carcinogenesis
of cervical cancer becomes manifest in CIN III lesions. J Clin
Pathol 58:1096–1100
158. Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact
of different classes of infiltrating Tcytotoxic and helper cells (Th1,
th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:
1263–1271
159. Kristensen VN, Vaske CJ, Ursini-Siegel J et al (2012) Integrated
molecular profiles of invasive breast tumors and ductal carcinoma
in situ (DCIS) reveal differential vascular and interleukin signal-
ing. Proc Natl Acad Sci USA 109:2802–2807
160. Gaur P, Singh AK, Shukla NK et al (2014) Inter-relation of Th1,
Th2, Th17 and Treg cytokines in oral cancer patients and their
clinical significance. Hum Immunol 75:330–337
161. Datta J, Berk E, Xu S et al (2015) Anti-HER2 CD4(+) T-helper
type 1 response is a novel immune correlate to pathologic response
following neoadjuvant therapy in HER2-positive breast cancer.
Breast Cancer Res 17
162. Peng D, Kryczek I, Nagarsheth N et al (2015) Epigenetic silencing
of TH1-type chemokines shapes tumour immunity and immuno-
therapy. Nature 527:249–253
163. Si W, Huang W, Zheng Yet al (2015) Dysfunction of the recipro-
cal feedback loop between GATA3- and ZEB2-nucleated repres-
sion programs contributes to breast cancer metastasis. Cancer Cell
27:822–836
164. DeML,Wormann S, Brunetto E et al (2016) Basophil recruitment
into tumor-draining lymph nodes correlates with Th2 inflamma-
tion and reduced survival in pancreatic cancer patients. Cancer Res
76:1792–1803
165. Nagarsheth N, Peng D, Kryczek I et al (2016) PRC2 epigenetically
silences Th1-type chemokines to suppress effector T-cell traffick-
ing in colon cancer. Cancer Res 76:275–282
166. Subbaramaiah K, Morris PG, Zhou XK et al (2012) Increased
levels of COX-2 and prostaglandin E2 contribute to elevated aro-
matase expression in inflamed breast tissue of obese women.
Cancer Discov 2:356–365
Semin Immunopathol
